AnaptysBio, Inc.
10770 Wateridge Circle
Suite 210
San Diego
California
92121
United States
Tel: 858-362-6295
Fax: 858-362-6296
Website: http://www.anaptysbio.com/
Email: info@anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program in Phase 2 for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program. AnaptysBio is also developing imsidolimab, our anti-IL-36R antibody in Phase 3 for the treatment of generalized pustular psoriasis, or GPP. We also have additional preclinical programs and discovery research of potentially innovative immunology therapeutics, including ANB033, an anti-CD122 antagonist antibody for the treatment of inflammatory diseases. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
128 articles about AnaptysBio, Inc.
-
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
5/2/2023
AnaptysBio, Inc. (Nasdaq: ANAB) today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology.
-
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
4/6/2023
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately.
-
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/1/2023
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2022 and provided business updates.
-
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
2/27/2023
AnaptysBio, Inc. announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m. ET / 11:50 a.m. PT.
-
AnaptysBio Announces Stock Repurchase Plan
1/13/2023
AnaptysBio, Inc. today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share.
-
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
1/5/2023
AnaptysBio, Inc. announced a portfolio update including initiating development of its wholly owned best-in-class immune cell modulating antibodies in autoimmune and inflammatory diseases with large and significantly underserved patient populations.
-
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
12/2/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI.
-
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
11/21/2022
AnaptysBio, Inc. (Nasdaq: ANAB) today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.
-
AnaptysBio to Participate in Upcoming November 2022 Investor Conferences
11/9/2022
AnaptysBio, Inc. announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m.
-
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
11/8/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2022 and provided pipeline updates.
-
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
10/5/2022
AnaptysBio, Inc. today announced that GSK’s study PERLA met its primary endpoint of objective response rate (ORR) of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as assessed by blinded independent central review per RECIST v1.1.
-
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
9/12/2022
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned subsidiary of DRI Healthcare Trust for up to $45 million.
-
It's been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities. -
Shares of AnaptysBio are down more than 16% after imsidolimab failed to meet the endpoint in a Phase II trial assessing its efficacy in hidradenitis suppurativa. -
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
8/31/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced top-line data from its HARP Phase 2 trial for the treatment of moderate-to-severe hidradenitis suppurativa (HS).
-
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
8/8/2022
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates.
-
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/5/2022
AnaptysBio, Inc. (Nasdaq: ANAB), today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.
-
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
6/2/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference.
-
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
5/4/2022
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.
-
A roundup of last week's top clinical trial updates and news.